Cargando…

Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model

BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Yimam, Mesfin, Zhao, Jifu, Corneliusen, Brandon, Pantier, Mandee, Brownell, Lidia, Jia, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041641/
https://www.ncbi.nlm.nih.gov/pubmed/24891878
http://dx.doi.org/10.1186/1758-5996-6-61
_version_ 1782318699513905152
author Yimam, Mesfin
Zhao, Jifu
Corneliusen, Brandon
Pantier, Mandee
Brownell, Lidia
Jia, Qi
author_facet Yimam, Mesfin
Zhao, Jifu
Corneliusen, Brandon
Pantier, Mandee
Brownell, Lidia
Jia, Qi
author_sort Yimam, Mesfin
collection PubMed
description BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood glucose, fructosamine and plasma insulin level in humans and improved impaired glucose and insulin resistance in high-fat diet-induced and db/db non-insulin dependent diabetic mouse models. Here we describe activity of UP780 and its constituents to improve insulin sensitivity in alloxan induced insulin dependent diabetic mouse model. MATERIALS AND METHOD: Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Aloesin (UP394) was formulated with an Aloe vera inner leaf gel powder polysaccharide (Qmatrix) to yield a composition designated UP780. Efficacy of oral administration of UP780 at 2000 mg/kg and its constituents (aloesin at 80 mg/kg and Qmatrix at 1920 mg/kg) were evaluated in this model. Glyburide, a sulfonylurea drug used in the treatment of type 2 diabetes, was used at 5 mg/kg as a positive control. Effect of UP780 on non-diabetic normal mice was also addressed. RESULTS: Mice administered intraperitoneal alloxan monohydrate developed progressive type-1 diabetes like symptom. After 4 weeks of daily oral administration, reductions of 35.9%, 17.2% and 11.6% in fasting blood glucose levels were observed for UP780, the UP780 Aloe vera inner leaf gel polysaccharide preparation without chromone (Qmatrix), and Aloesin (UP394), treated animals respectively, compared to vehicle treated animals. UP780 has no impact on blood glucose level of non-diabetic healthy mice. UP780 showed statistically significant improvement for blood glucose clearance in oral glucose tolerance tests. Similarly, enhanced improvement in plasma insulin level and statistically significant reduction in triglyceride level was also observed for animals treated with the composition. CONCLUSION: These findings suggest that UP780, a chromone standardized Aloe based composition, could possibly be used as a natural supplement alternative to facilitate maintenance of healthy blood glucose levels.
format Online
Article
Text
id pubmed-4041641
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40416412014-06-03 Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model Yimam, Mesfin Zhao, Jifu Corneliusen, Brandon Pantier, Mandee Brownell, Lidia Jia, Qi Diabetol Metab Syndr Research BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood glucose, fructosamine and plasma insulin level in humans and improved impaired glucose and insulin resistance in high-fat diet-induced and db/db non-insulin dependent diabetic mouse models. Here we describe activity of UP780 and its constituents to improve insulin sensitivity in alloxan induced insulin dependent diabetic mouse model. MATERIALS AND METHOD: Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Aloesin (UP394) was formulated with an Aloe vera inner leaf gel powder polysaccharide (Qmatrix) to yield a composition designated UP780. Efficacy of oral administration of UP780 at 2000 mg/kg and its constituents (aloesin at 80 mg/kg and Qmatrix at 1920 mg/kg) were evaluated in this model. Glyburide, a sulfonylurea drug used in the treatment of type 2 diabetes, was used at 5 mg/kg as a positive control. Effect of UP780 on non-diabetic normal mice was also addressed. RESULTS: Mice administered intraperitoneal alloxan monohydrate developed progressive type-1 diabetes like symptom. After 4 weeks of daily oral administration, reductions of 35.9%, 17.2% and 11.6% in fasting blood glucose levels were observed for UP780, the UP780 Aloe vera inner leaf gel polysaccharide preparation without chromone (Qmatrix), and Aloesin (UP394), treated animals respectively, compared to vehicle treated animals. UP780 has no impact on blood glucose level of non-diabetic healthy mice. UP780 showed statistically significant improvement for blood glucose clearance in oral glucose tolerance tests. Similarly, enhanced improvement in plasma insulin level and statistically significant reduction in triglyceride level was also observed for animals treated with the composition. CONCLUSION: These findings suggest that UP780, a chromone standardized Aloe based composition, could possibly be used as a natural supplement alternative to facilitate maintenance of healthy blood glucose levels. BioMed Central 2014-05-24 /pmc/articles/PMC4041641/ /pubmed/24891878 http://dx.doi.org/10.1186/1758-5996-6-61 Text en Copyright © 2014 Yimam et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yimam, Mesfin
Zhao, Jifu
Corneliusen, Brandon
Pantier, Mandee
Brownell, Lidia
Jia, Qi
Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title_full Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title_fullStr Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title_full_unstemmed Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title_short Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
title_sort blood glucose lowering activity of aloe based composition, up780, in alloxan induced insulin dependent mouse diabetes model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041641/
https://www.ncbi.nlm.nih.gov/pubmed/24891878
http://dx.doi.org/10.1186/1758-5996-6-61
work_keys_str_mv AT yimammesfin bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel
AT zhaojifu bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel
AT corneliusenbrandon bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel
AT pantiermandee bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel
AT brownelllidia bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel
AT jiaqi bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel